Research programme: Alzheimer's disease therapeutics - Selonterra

Drug Profile

Research programme: Alzheimer's disease therapeutics - Selonterra

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selonterra
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 23 Jan 2017 Research programme: Alzheimer's disease therapeutics - Selonterra is available for licensing as of 23 Jan 2017. http://www.selonterra.com
  • 23 Jan 2017 Selonterra files for patent protection for Alzheimer's disease therapeutics (Selonterra website, January 2017)
  • 18 Jan 2017 Early research in Alzheimer's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top